Connect with us


Agency of the Year Category 1 – FCB Health New York: 2022

In spite of all the chaos 2021 unleashed on the world, it was another incredible year of growth and innovation at FCB Health NY, according to the leadership…



Agency of the Year Category 1: FCB Health New York, An IPG Health Company

100 West 33rd Street, New York, NY 10001
212-672-2300 •



Account wins 27
Active business clients 43

Brands by 2021 sales
Brand-product accounts held 85
$25 million or less 5
$25 million-$50 million 5
$50 million-$100 million 8
$100 million-$500 million 18
$500 million-$1 billion 10
$1 billion or more 5
Products not yet approved/launched 20


Services Mix

HCP 50%


WINNER | Best Consumer Print Campaign
More than 16 million people living with chronic dry eye (CDE) feel like their eyes are under assault 24/7. Even in a market saturated with OTC and prescription options, they struggle to find adequate relief. The Cequa “Battle Back” campaign cuts through the noise and introduces CDE suffers to a prescription medicine that treats differently, with creative that speaks to their needs differently.

Client Roster

BioXcel Therapeutics
Boehringer Ingelheim
Cara Therapeutics
Cooper Surgical
Crohn’s & Colitis Foundation
CSL Behring
Day One Biopharmaceuticals
Exact Sciences
Jazz Pharmaceuticals
Kyowa Kirin
Ono Pharma
Sanofi Genzyme
Seattle Genetics/Astellas
Sierra Oncology
Sun Pharmaceuticals


WINNER | Best Social Media Campaign
At the initial rollout of COVID-19 vaccines, over half of all LGBTQ+ adults were vaccine-hesitant due to mistrust of the healthcare system. This was largely fueled by misinformation on social media: Facebook and Twitter account for about 72 percent of the rumors and conspiracy theories around the COVID-19 vaccine. FCB Health partnered with GMHC for a social-first campaign to shut down misinformation at its source.


Agency of the Year, Category I
Best Consumer Print Campaign
Best Social Media Campaign


Best Consumer TV/Radio Campaign
Best Digital Physician Campaign
Best Social Media Campaign


In spite of all the chaos 2021 unleashed on the world, it was another incredible year of growth and innovation at FCB Health NY, according to the leadership team.

“As the single largest healthcare marketing agency in the world, we use our incredible growth to fuel the future, creating mammoth opportunities in the industry for our clients, their brands, and our people. Our relentless drive, never finished spirit, and distinct and unbreakable culture continue to position us for success, even during these challenging times,” management says.

“Big things continue to happen here, year after year. When you work with FCB Health NY, you immediately recognize that you’re in the big leagues. Things are just different here. Our recipe for success isn’t complicated – being passionately committed to doing what’s right for our clients, their brands, and our people – and the growth, best-in-class work, and wins continually follow. The continuity of our success across all key areas – culture, creativity, and revenue growth – sets us apart and keeps us driving forward.”

Management says, “While it’s easy to quantify business and creative success with numbers and trophies, culture can be harder. Yet year after year we manage to land on multiple ‘Best Place to Work’ lists. And this year, for the first time, we were even honored as an Ad Age ‘Best Place to Work,’ an achievement that we’re most proud of, particularly given the context of the last two years.”

“Our ability to continue to foster a strong culture, deliver extraordinary results for our clients, and produce industry-leading work is something I’m incredibly proud of,” says Dana Maiman, CEO of IPG Health. “None of our success would be possible without the talented and dedicated individuals who make up the agency, and our ongoing commitment to doing the right thing for our clients and each other.”

The leadership team says FCB Health NY’s success affords it tremendous opportunity.

“We are able to invest heavily in our offerings and resources – pushing boundaries in tech, enhancing our data solutions, and strengthening our already significant creative muscle,” according to agency executives. “We also invest heavily in our people’s growth. Our growth mindset is never just focused on the business, it extends directly to our people. Every new client assignment brings with it new opportunities to do something incredible. We fundamentally understand that this type of investment yields the best kind of return.”

Recent Accomplishments

Our never finished, entrepreneurial approach is always driving us forward, delivering BIG results,” management says. “In 2021, we experienced phenomenal 25 percent growth on an already industry-leading base, and achieved 27 major wins with 21 new brand assignments, adding to our impressive client roster.” These new wins included Alexion, BioXcel, Day One Biopharmaceuticals, Inflammatix, Novartis, Omeros, and UCB. “We are committed to exceeding our clients’ expectations time after time, and our clients clearly recognize that: organic growth from existing clients represents a stunning 50.2 percent of our growth, with the remainder coming from new clients.”

Agency leaders say, “Our 1,300+ talented employees are the heart of our business. In 2021, we welcomed an incredible 521 new hires – including 30+ ‘boomerangs’ (people who left FCB Health New York and came back after a short time) and celebrated 308 promotions. We bolstered our creative bench and welcomed industry heavyweights Megan Williams as group creative director, Arun Nemali as group creative director, and John Kelly as creative director. Bryan Gaffin returned as executive creative director and Dave Gehrke also returned as group creative director. We also hired Jenna Brownstein as group management director and Elise Whitaker as director of conversational experiences.”

“We continue to attract and retain the top talent in the industry, and we couldn’t be more proud,” says Kathleen Nanda, chief creative officer of FCB Health New York. “Our people are the reason we’ve had such extraordinary growth and are able to consistently create the breakthrough and award-winning work we’re known for.”

FCB Health New York garnered many industry accolades and achievements last year, including “The Trial for #Clinical­Equality” winning Best Social Media at the Manny Awards, as well as a Bronze – Design (Pharmaceutical) – Digital/Mobile at Clio Health, a Bronze – Health/Pharma: Integrated: Health & Disease Awareness & Advocacy at New York Festivals, and a Bronze – Non-Profit Strategy at the Jay Chiat Awards.

“Blood Vessels” (GMHC) took home Silver: Consumer Print Campaign at the MM+M Awards. Other award wins included four trophies at the Creative Floor Awards (Art Direction, Illustration, Poster Campaign, Print Campaign) and ANA Multicultural Excellence Awards (Print).

Colace, a small heritage stool softener brand, has been outspent and outshelved by competitors for years. To grow, FCB Health needed to not only differentiate and reinvigorate Colace, but do it in an outsized way.

“Healing the Healers” (Sermo) took home Silver: Digital Initiative for Non-Consumers (HCPs, sales reps, etc.) at the MM+M Awards. Power Couple” (Senokot) was named a Platinum Winner in Video at the Clio MUSE Creative Awards 2021. Poop Should Never Feel Painful” (Colace) took home four Platinum wins at the MarCom Awards (Video/Audio – TV – Single Spot, Video/Audio – Film – Video Script, Video/Audio – Digital Video Creation – Animation, Video/Audio – Audio/Radio – Original Music), and Gold (TV Ad Campaign) and Platinum (TV Ad, Music, Animation) at the Clio MUSE Creative Awards.

FCB Health New York was crowned one of the most creative agencies in the world on Advertising Health’s World Top 10 in partnership with The Creative Floor Superstars program, celebrating the world’s most awarded health and wellness creative campaigns, and the agencies that made them.
Additionally, Maiman was recognized as Ad Age 2021’s “Agency Executive of the Year,” marking the first time the publication awarded this distinction to a healthcare advertising leader.

“Despite all our success, we’re never finished thinking of new ways to enhance our work and advance our workplace culture,” agency executives say. “Last year, we launched Write It Forward, an initiative that recruits, trains, and mentors diverse writing talent from all walks of life for entry-level, science-focused copywriting positions. Our inaugural class had 20 people, with 18 accepting full-time positions. In 2022, the program will expand across departments and across the broader IPG Health network.”

According to agency management, “Keeping our people connected, engaged and inspired remains a priority. At FCB Health New York, we launched ‘Let’s Talk,’ a series of conversations hosted by employees highlighting different creative topics like art direction, big data, shoots, data visualization, and more. Since its introduction last year, the conversations have been attended by hundreds of people and reinforce our community and culture-building at the agency.

“Because we know how difficult the past two years have been, it’s also important to take a moment to pause and acknowledge what we’ve been through together. On March 22, 2021, the one-year anniversary of going fully remote, we took the ‘WF’ out of WFH and gave our people the day off, so they could make home just home again. This was a small token of appreciation to our teams for welcoming our offices into their homes with commitment and dedication.”

Structure and Services

When it comes to opportunity, FCB Health New York is truly the big leagues, according to the agency managers. “Our scale gives our people unmatched opportunity to work across a portfolio of industry-changing therapeutics and our clients access to the deepest and most diverse talent in the industry, across every discipline,” says Mike Guarino, chief commercial officer of IPG Health.

“We are doing big things, and the depth and breadth of opportunity enables our people to elevate their experience and accelerate their careers in a way that just isn’t possible elsewhere,” Nanda says. “While our size offers much opportunity, just being the biggest isn’t enough – it’s about being the best, and that’s what we remain focused on year after year.”

According to the managerial team, the agency continued to lean into flexibility, accountability, and trust with its “work appropriately” philosophy, anchored by an unwavering commitment from executive leadership. “And our incredible production team helped us sail through endlessly complex COVID-related production challenges, executing an astonishing 90+ shoots and 23 launches in 2021.”

“We continued to advance our best-in-class experience design (XD) team, expanding our NY team and adding teams in South Africa, with further global expansion imminent. This allows us to leverage cutting-edge talent, while creating a ‘follow-the-sun’ model, elevating the level of service we provide for our clients,” management says.

“Doubling down on our leadership position, we launched a MarTech offering (Marketing Technology) focused on enabling omnichannel strategies for our clients. We are also actively building an Accessibility practice to ensure that the experiences we create are inclusive to all, regardless of disability status. As you can imagine, the profile and expertise of our talent has continued to evolve, enabling us to find new and better ways to add value to our clients.”

In July 2021, FCB Health NY became part of the newly created IPG Health Network, integrating with other IPG Health agencies and giving the agency increased access to a variety of best-in-class resources from one of the largest and most-awarded health communications networks in the world.

“At FCB Health New York, we are committed to creating a work environment in which everyone can be their truest and best self,” executives say. “Diversity, equity and inclusion (DEI) are foundational to our culture and our creativity, and embedded into every touchpoint of our employees’ journey through a variety of programs.”

These programs include the Inclusive Managers Toolkit (IMT), a mandatory 10-week program designed to provide all managers with the skills and resources to thrive by exploring who they are as leaders, how they lead their teams, and their impact on the organizational strategy and success, all through a DEI lens; and the Employee Relations Group, which is dedicated to fostering a culture of equity, respect and healthy working relationships across the agency.

Other initiatives are FCBWE, the employee-led Diversity & Inclusion Council, committed to creating interconnectivity and promoting diversity across the network; and Chats for Change. FCBWE offers peer-to-peer learning opportunities and activities around critical diversity issues that matter to our employees year-round. Chats for Change is a new initiative that equips employees with the skills to have more conscious conversations in their day-to-day work lives.

The agency remains focused on developing and supporting the best and most diverse talent, and continued The Residency, a six-week program for new hires who are new to healthcare.

“Our talent philosophy for championing our people continues to be PCM (Proactive Career Management),” management says. “PCM is our approach to empowering our people to proactively explore their potential and take control of their career journey within our agency and the broader IPG Health network. The depth and breadth of our client roster, as well as our learning and development opportunities affords our people the greatest opportunities to change disciplines, brands, clients, or even regions.”

“Our people are the heart of our business, and because we are never finished – never finished learning, never finished evolving, and never finished growing – we have a responsibility to ensure they have endless opportunities to grow and develop new skills, apply their strengths and interests to new experiences, and be challenged in a variety of ways,” Maiman says. “We know everyone has choices, and people choose to be here because they see that we understand our responsibility to help grow, develop and train them. That’s why we have always been proponents of proactive career management (PCM), and the advent of IPG Health has allowed us to do it in an even bigger way and fulfill our responsibility to our people.”

Future Plans

As an agency, everything we create – both internally and externally – is grounded in DEI best practices and in 2022, we will dig even deeper to ensure it remains fundamental to our ongoing evolution and growth,” management says.

“At FCB Health NY, we embody a start-up, disruptive spirit across all departments, and every level. Our mantra, ‘Never Finished,’ is put in to play on each and every business challenge we face. Just when you think we’ve done it all, we find something new to spark our fire. It’s really an amazing thing to be a part of. Our passion for doing the right thing has allowed us to stay laser-focused on what really matters: doing what’s right for our clients, their brands, and our people. As you can see from our results, it’s clearly a winning strategy.”


At FCB Health New York, we have an enduring commitment to giving back and leaving the world better than we found it,” agency executives say. “We can afford to invest time and resources to support the causes that our people care about the most. Through our pro bono work, we support and shine a light on societal issues and communities that in the past have been underrepresented.”

On World Cancer Day 2021, the agency launched the award-winning “The Trial for #ClinicalEquality,” an initiative dedicated to achieving racial equity in clinical trials. “This is a cause that we remain committed to and there’s so much more to come in 2022,” managers say.

FCB Health NY also partnered with the Dorney-Koppel Foundation, the COPD Foundation and the American Respiratory Care Foundation to create “COPD SOS,” a PSA dedicated to finding the millions of Americans living with undiagnosed COPD, and getting them vaccinated against COVID-19, as this population is particularly vulnerable.

The agency continued its award-winning Blood Equality initiative, a partnership with the Gay Men’s Health Crisis (GMHC) to achieve blood equality. This initiative included the launch of its most recent project, Blood Vessels, which was accepted into the Victoria & Albert Museum’s permanent collection last year, cementing it as a part of history and culture.

The agency joined forces with GMHC for its latest campaign, “Ms. Information,” to help get LGBTQ+ individuals vaccinated against COVID-19 and to shut down the misinformation brewing on social media. This campaign inspired “VaxxFacts @ IPG Health,” a virtual live panel discussion and Q&A, featuring Sommer Bazuro, Ph.D., chief medical officer at FCB Health, and Dan Carucci, M.D., Ph.D., global chief medical officer at McCann Health answering pre-submitted COVID-19 vaccine-related questions from across the IPG network.

The agency continued its “Disappearing Doctors” initiative, dedicated to prioritizing the mental health of physicians who experience mental health issues such as burnout and suicide at a higher rate than the general population yet are often unable to ask for help without risking their careers. In 2021 the agency partnered with the ALL IN Foundation, a coalition between Dr. Lorna Breen Foundation, Thrive Global, and First Responders First, to create the “All in Pledge.” The pledge highlights the changes needed with regards to how physician mental health is addressed across the healthcare system. FCB Health NY collaborated with Ending Physician Burnout and joined MTV Entertainment Group’s multi-year initiative, “Mental Health is Health,” to tackle the nation’s growing mental health crisis.

(top row left to right) Kitty Ravenhall, executive VP, executive director, strategic planning; Sommer Bazuro, Ph.D., executive VP, chief medical officer, FCB Health;
Bill Yorio, executive VP, executive director; Suzanne Molinaro, executive VP, director of production; Kamran Aslam, senior VP, director, technology; Kerry Dwyer, executive VP, executive director
(middle row left to right) Sarah Hall, executive VP, executive director; Mike Guarino, chief commercial officer, IPG Health; Dana Maiman, CEO, IPG Health; Kathleen Nanda, chief creative officer; Jonathan Brady, executive VP, group engagement director
(bottom row left to right) Jennifer Samuels, executive VP, executive director; Julia Phelan, executive VP, executive director; Mike Devlin, executive VP, executive creative director; Wendi Goodman, executive VP, executive director; Matt Bergin, senior VP, editorial director; Laura Mizrahi, executive VP, executive creative director


Read More

Continue Reading


FDA to soon authorize Pfizer’s COVID booster shot for younger kids – NYT

U.S. health regulators are expected to authorize a booster shot of Pfizer/BioNTech’s COVID-19 vaccine for children aged 5 to 11 as soon as May 17, the…



FDA to soon authorize Pfizer’s COVID booster shot for younger kids – NYT

(Reuters) – U.S. health regulators are expected to authorize a booster shot of Pfizer (PFE.N)/BioNTech’s COVID-19 vaccine for children aged 5 to 11 as soon as Tuesday, the New York Times reported on Monday, citing people familiar with the matter.

The companies submitted an application to the U.S. Food and Drug Administration for the authorization last month.

They have cited data from a mid- to late-stage study showing a third dose of their shot increased protection against the original coronavirus version and the Omicron variant among children in the age group. read more

It is unclear how much demand there is for the third dose in the age group. Just 28.8% of children aged 5 to 11 are fully vaccinated, according to data from the U.S. Centers for Disease Control and Prevention.

Empty vials of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine are seen at The Michener Institute, in Toronto, Canada January 4, 2021 in this file photo. REUTERS/Carlos Osorio/File Photo

A meeting of outside vaccine experts on an advisory committee to the Centers for Disease Control and Prevention has been scheduled for Thursday, the report said.

The FDA declined to comment, while Pfizer and BioNTech did not respond to requests for comment.

Reporting by Mrinalika Roy in Bengaluru; Editing by Anil D’Silva

Our Standards: The Thomson Reuters Trust Principles.


Reuters source:


Read More

Continue Reading


FDA declines to authorize common antidepressant as COVID treatment

The U.S. Food and Drug Administration decided not to authorize the antidepressant fluvoxamine to treat COVID-19, saying the data has not shown the drug…



FDA declines to authorize common antidepressant as COVID treatment

By  and

(Reuters) – The U.S. Food and Drug Administration has decided not to authorize the antidepressant fluvoxamine to treat COVID-19, saying that the data has not shown the drug to be an effective therapeutic for fighting the virus.

“Based on the review of available scientific evidence, the FDA has determined that the data are insufficient to conclude that fluvoxamine may be effective in the treatment of nonhospitalized patients with COVID-19 to prevent progression to severe disease and/or hospitalization,” the agency said in a document published on Monday.

University of Minnesota professor Dr. David Boulware submitted the emergency use authorization request to the FDA that would have allowed doctors to prescribe fluvoxamine maleate to treat COVID-19 in non-hospitalized patients.

The generic drug belongs to an old, widely-used class of antidepressants called selective serotonin reuptake inhibitors, or SSRIs.

Boulware said that his request is less urgent with the availability of drugs like Pfizer Inc’s (PFE.N) Paxlovid, but he still believes the data supports the drug’s use in some COVID patients.

“There are effective therapeutics that are available. But not everyone has access to them. Not everyone can tolerate them. Some people have contraindications,” Boulware said in an interview. “And if you go elsewhere in the world, low- and middle-income countries, they have access to no therapeutics.”

Boulware’s submission relied on data from three trials, especially a study of 1,497 non-hospitalized COVID patients in Brazil.

While the Brazilian study met its primary endpoint, showing a roughly 30% drop in hospitalizations in the group that received fluvoxamine, the FDA said there were uncertainties about the assessment, which measured reduction in emergency department visits lasting more than 6 hours.

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo

Boulware said FDA had used a different measure to count hospitalizations in other drug trials, including only acute care that lasted at least 24 hours.

“The standard that they were holding for fluvoxamine was a different standard than the other big pharma trials, with Paxlovid and (Merck’s) molnupiravir and the monoclonals,” he said of other authorized COVID therapeutics.

“I was really quite disappointed that they did that,” he said.

Reporting by Leroy Leo in Bengaluru and Michael Erman in New Jersey; Editing by Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles.


Reuters source:


Read More

Continue Reading

Spread & Containment

Coronavirus may be linked to cases of severe hepatitis in children

A chain of events possibly triggered by unrecognized infection with the SARS-CoV-2 coronavirus could be causing the mysterious cases of severe hepatitis…



Coronavirus may be linked to cases of severe hepatitis in children


(Reuters) – The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.

SARS-CoV-2 could be at root of mysterious hepatitis in kids

A chain of events possibly triggered by unrecognized infection with the SARS-CoV-2 coronavirus could be causing the mysterious cases of severe hepatitis reported in hundreds of young children around the world, researchers suggest.

Children with COVID-19 are at significantly increased risk for liver dysfunction afterward, according to a report posted on Saturday on medRxiv ahead of peer review. But most of the children with acute hepatitis – which is generally rare in that age group – do not report a previous SARS-CoV-2 infection. Instead, the majority have been found to be infected with an adenovirus called 41F, which is not known to attack the liver. It is possible that the affected children, many of whom are too young to be vaccinated, may have had mild or asymptomatic COVID infections that went unnoticed, a separate team of researchers suggest in The Lancet Gastroenterology & Hepatology. If that were true, they theorize, then lingering particles of the coronavirus in the gastrointestinal tract in these children could be priming the immune system to over-react to adenovirus-41F with high amounts of inflammatory proteins that ultimately damage the liver.

A firefighter from the Marins-Pompiers of Marseille (Marseille Naval Fire Battalion) administers a nasal swab to a child at a testing site for coronavirus disease (COVID-19) in Marseille, France, September 17, 2020. REUTERS/Eric Gaillard

“We suggest that children with acute hepatitis be investigated for SARS-CoV-2 persistence in stool” and for other signals that the liver damage is happening because the spike protein of the coronavirus is a “superantigen” that over-sensitizes the immune system, they said.

Face-down position unhelpful for awake patients

For hospitalized COVID-19 patients who are breathing on their own but with supplemental oxygen, lying face down might not help prevent them from eventually needing mechanical ventilation, according to a new study.

In the study, 400 patients were randomly assigned to usual care or to standard care plus intermittently lying on their stomach, a position known to improve the course of illness in sedated patients on mechanical ventilators. Over the next 30 days, 34.1% in the prone-positioning group and 40.5% in the usual-care group needed to be intubated and put on a ventilator, a difference that was not statistically significant. There might have been a reduction in the risk for intubation with prone positioning among some of the patients, researchers said on Monday in JAMA, but they could not confirm it statistically from their data. The average duration of prone positioning per day was roughly five hours, less than the target of eight to 10 hours per day.

“Long hours of awake prone positioning are challenging and highly influenced by patient comfort and preference,” the researchers said. “The most common reason for interruption of prone positioning was patient request, which might have been related to overall subjective improvement or related to discomfort from prone positioning.”

Click for a Reuters graphic on vaccines in development.

Reporting by Nancy Lapid and Megan Brooks; Editing by Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles.


Reuters source:


Read More

Continue Reading